Matches in Nanopublications for { ?s ?p "DDI between Dihydroergotamine and Delavirdine - Delavirdine, a strong CYP3A4 inhibitor, may increase the serum concentration of dihydroergotamine by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dihydroergotamine if delavirdine is initiated, discontinued or dose changed. [drugbank_resource:DB00320_DB00705]"@en ?g. }
Showing items 1 to 1 of
1
with 100 items per page.
- drugbank_resource:DB00320_DB00705 label "DDI between Dihydroergotamine and Delavirdine - Delavirdine, a strong CYP3A4 inhibitor, may increase the serum concentration of dihydroergotamine by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dihydroergotamine if delavirdine is initiated, discontinued or dose changed. [drugbank_resource:DB00320_DB00705]" assertion.